Overview

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

Status:
Completed
Trial end date:
2019-03-22
Target enrollment:
Participant gender:
Summary
An open label study will be performed on 80 people with HIV infection who are maintained on effective treatment with antiretroviral drugs.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AIDS Healthcare Foundation
Collaborator:
HIV Immunotherapeutics Institute
Treatments:
Mesalamine